Email Address
Please enter your official email address
We notice that your permissions preference cookie is missing. Please enter your email address so we can determine if you need to complete a permission form or verify that you have already completed this form. Receiving permission from our users is an important part of our compliance with international privacy regulations. Your email address will not be shared without your permission. Please refer to our
privacy policy
for information on how we protect your personal information.
Welcome to AdisInsight
We need some information from you before you start using the platform.
This information will allow us to better understand how AdisInsight is being used.
It does not require or replace the individual login accounts that many of you use to save searches and create email alerts.
Protecting your personal information is important.
That is why AdisInsight collects the minimum amount of information necessary to enable functionality, report usage, and contact you with information about AdisInsight.
For further information on how we protect and process your personal information, please refer to our
privacy policy.
Terms of Service
By accessing or using the AdisInsight platform you agree to the terms of use.
Please select terms of use
How much you and your colleagues use AdisInsight often determines if your organization will continue paying to provide access to the platform.
The number of times you access AdisInsight, the number of searches you performed, and the number of profiles you viewed will be provided to your organization both in aggregate with other users and individually by your email address.
You have the right to opt-out of sharing your email address with your organization but doing so may negatively affect your organization’s decision to renew their subscription to AdisInsight. If you opt-out your email will still be collected for registration purposes.
Please choose your email permissions
Get more from AdisInsight
Keep up to date with all things AdisInsight by signing up to receive our product bulletin, which includes related content from Springer Nature such as white papers, product news, industry commentaries, and webinar invites, straight to your inbox. Unsubscription is always possible via email.
Please choose your permissions
Mandatory field
Please enter your official email address
Research programme: polytope monoclonal antibody therapeutics - ImmunoPrecise Antibodies
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
No
New Molecular Entity
Yes
Highest Development Phases
Research
COVID 2019 infections
Most Recent Events
23 Nov 2020
ImmunoPrecise Antibodies plan a preclinical study in SARS-CoV-2 in ealy January 2021 in Netherlands
13 Jul 2020
ImmunoPrecise Antibodies intends to initiate pre-clinical evaluations in Summer 2020
22 Jun 2020
ImmunoPrescise Antibodies and LiteVax agree to conduct preclinical trials of polytope vaccine candidates for COVID-2019 infections
Development Overview
Introduction
Polytope monoclonal antibody candidates are being developed by ImmunoPrecise Antibodies (IPA) in collaboration with EVQLV for the treatment of COVID-19 infections. EVQLV, an artificial intelligence company will utilise B cell selectTM, Single Step Cloning Hybridoma, and custom DeepDisplayTM platforms developed at IPA. B cell selectTM platform enables the interrogation of B-cells to generate native monoclonal antibodies from any immunised animal, independent of species. DeepDisplayTM platform is a combination of phage display platform which contains immune libraries from different animal species including transgenic animals and Ligand's OmniAb therapeutic antibody platform which develop fully human antibody with reduced immunogenicity. EVQLV will perform in-silico antibody design to discover novel antibody sequence to leverage lead candidate from IPA's discovery platform. Early research is underway in US.
Company Agreements
In June 2020, ImmunoPrecise Antibodies (IPA) and LiteVax entered an R & D agreement to conduct preclinical studies for analysis of the immunogenicity, safety and potency of ImmunoPrecise Antibodies' SARS-CoV-2 vaccine candidates, upon being formulated with LiteVax’s Adjuvant (LVA). The studies have been completely funded by TRANSVAC2, a network of leading European groups working in the field of vaccine development. The aim of this collaboration is to conduct preclinical analyses with PA’s protein-based vaccine candidates that are formulated with LVA (adjuvant) and assess for the potent, neutralizing antibody responses against SARS-CoV-2 infection in a swine model. Protein-based vaccine candidates will be supplied by ImmunoPrecise and LVA will be supplied by LiteVax. According to the agreement, both companies will retain full rights to their respective proprietary assets and know-how used for the study. If the preclinical studies are a success, IPA and LiteVax may negotiate the terms for a preclinical study in a second animal model, and the details of the potential commercialization of any resulting vaccine. Financial details of the agreement have not been disclosed.[1]
In March 2020, ImmunoPrecise Antibody and EVQLV entered into research collaboration to develop lead therapeutic and vaccine candidate against COVID-19. Under the terms of the agreement, EVQLV will perform in silico antibody design and discovery to generate novel, optimized antibody sequences leveraging lead candidate data from IPA’s discovery technologies, as well as previously published sequences. EVQLV will utilise its in-silico antibody design to generate novel antibody sequence by using IPA's B cell selectTM and custom deep displayTM technology platform to discover lead candidate against SARS-CoV-2 coronavirus infection.
Key Development Milestones
In November 2020, ImmunoPrecise Antibodies announced nomination of the first cocktail consisting of four, human, synergistic antibodies to enter pre-clinical testing that will evaluate its safety, tolerability and efficacy in the well defined SARS-CoV-2, Syrian hamster model[2].
ImmunoPrecise Antibodies, in July 2020, announced the identification of additional human lead antibody candidates against SARS-CoV-2, that demonstrate potent in vitro neutralizing activity, and have been discovered using Ligand's OmniRat® therapeutic human antibody platform[3].In June 2020, ImmunoPrecise announced discovery of functional antibodies from the top 300 lead antibodies analysed from human and llama[4].
In June 2020, ImmunoPrecise Antibodies announced that they intend to conduct preclinical trial with polytope monoclonal antibody candidates in collaboration with LiteVax in August 2020. The preclinical study will determine immunogenicity, safety and potency of the candidates with an adjuvant provided by LiteVax. The study will be funded by TRANSVAC2[5].
In March 2020, EVQLV submitted the first panel of candidate therapeutic antibody sequences, comprised of DNA sequences encoding for potentially therapeutic antibodies against the new coronavirus, SARS-CoV-2[6].
ImmunoPrecise Antibodies plan a preclinical study in SARS-CoV-2 in ealy January 2021 in Netherlands [2]
01 Dec 2020
30 Dec 2020
Trial Update
ImmunoPrecise Antibodies intends to initiate pre-clinical evaluations in Summer 2020 (9297738)
15 Jul 2020
Development History
Event Date
Update Type
Comment
23 Nov 2020
Trial Update
ImmunoPrecise Antibodies plan a preclinical study in SARS-CoV-2 in ealy January 2021 in Netherlands [2]
Updated 01 Dec 2020
13 Jul 2020
Trial Update
ImmunoPrecise Antibodies intends to initiate pre-clinical evaluations in Summer 2020 [3]
Updated 15 Jul 2020
22 Jun 2020
Licensing Status
ImmunoPrescise Antibodies and LiteVax agree to conduct preclinical trials of polytope vaccine candidates for COVID-2019 infections [5]
Updated 30 Jun 2020
18 Mar 2020
Phase Change
Early research in Coronavirus infections in USA (Parenteral) (ImmunoPrecise Antibody Website, March 2020)
Updated 26 Mar 2020
17 Mar 2020
Licensing Status
ImmunoPrecise Antibodies and EVQLV entered into research collaboration to develop lead therapeutic and vaccine candidate against SARS-CoV-2 coronavirus infection
Updated 26 Mar 2020
References
Collaborative COVID-19 Vaccine Project Between ImmunoPrecise Antibodies Europe and LiteVax BV, Funded Through TRANSVAC2. Internet-Doc 2020;.
ImmunoPrecise's Artificial Intelligence Partner, EVQLV, Submits First Panel of Optimized Antibody Sequences to Coronavirus for PolyTope(TM) mAb Therapy Program.
